Open AccessKey concepts in biosimilar medicines: what physicians must know
Author(s) -
Alper B. İskit
Publication year - 2021
Publication title -
i̇stanbul kuzey klinikleri
Language(s) - English
Resource type - Journals
ISSN - 2148-4902
DOI - 10.14744/nci.2021.84669
Subject(s) - biosimilar , medicine , product (mathematics) , key (lock) , alternative medicine , intensive care medicine , biological drugs , risk analysis (engineering) , pharmacology , immunology , computer science , rheumatoid arthritis , pathology , geometry , computer security , mathematics
Biologics' are a class of medications produced by living cells using recombinant DNA technology. Biologics have had an important impact in many areas of medicine, and in particular in rheumatology and oncology. However, the high cost of these agents is a growing concern, particularly as more products become available and their use for the treatment of immune-mediated inflammatory diseases continues to expand. Biosimilars, also called follow-on biologics, have been viewed as a potential cost-saving alternative to traditional therapies. Currently, a product can be considered biosimilar to a reference product if there are no clinically meaningful differences in terms of safety, purity, and potency. In this review, the most important key concepts about biosimilars were summarized for physicians emphasizing the status in Turkey.